BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Axsome Therapeutics (NASDAQ:AXSM)

2 posts

Biotech NewsWall Street Isn’t Watching This CNS Stock Yet — But Axsome Therapeutics (AXSM) Might Be the Breakout

  • BioTech Health X
  • December 31, 2025
What began as a focused effort to rethink how brain disorders are treated has quietly grown into one…
0 Shares
0
0
0
0
0
0
0

Biotech NewsDon’t Let the 70.7% YTD Jump Fool You—Axsome Therapeutics (AXSM) Still Faces Massive Downside Risk

  • BioTech Health X
  • December 2, 2025
Axsome Therapeutics (NASDAQ:AXSM) is a clinical-stage biopharmaceutical company that has grown into one of the most closely watched…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
  • Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
  • Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
  • Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
  • The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • February 13, 2026
    PMV Pharmaceuticals (PMVP) Forecast 2026: One Mutation, One Oral Drug, and a Re-Rating That Could Hit Fast
    • February 13, 2026
    Oncolytics (ONCY) Is a $90M “Science vs. Reality” Fight—And 2026 Is When Pelareorep Has to Win
    • February 13, 2026
    Nkarta (NKTX)’s Plot Twist: From Cancer Chaos to Autoimmune “Immune Reset” Hype
    • February 13, 2026
    Context (CNTX)’s Glow-Up: From “Old Thesis” to T-Cell Engager Chaos (In a Good Way)
    • February 13, 2026
    The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
Recent Posts
  • Verastem (VSTM) Isn’t “Small-Cap Roulette” Anymore—It’s a Commercial Oncology Ramp With a 2026 Twist
    • February 13, 2026
  • The Market Cap Is Small, the Idea Is Huge: Can Allogene (ALLO) Make CAR-T as Easy as Ordering a Drug?
    • February 13, 2026
  • 44% Real-World Response? Iovance (IOVA) Just Made “Off-the-Bench” Data the New Headline
    • February 13, 2026
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (5)
  • Biotech News (787)
  • Uncategorized (2)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top